Francesco Giotta

2.3k total citations
98 papers, 1.1k citations indexed

About

Francesco Giotta is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Francesco Giotta has authored 98 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 28 papers in Cancer Research. Recurrent topics in Francesco Giotta's work include Cancer Treatment and Pharmacology (35 papers), HER2/EGFR in Cancer Research (26 papers) and Breast Cancer Treatment Studies (25 papers). Francesco Giotta is often cited by papers focused on Cancer Treatment and Pharmacology (35 papers), HER2/EGFR in Cancer Research (26 papers) and Breast Cancer Treatment Studies (25 papers). Francesco Giotta collaborates with scholars based in Italy, United States and Malaysia. Francesco Giotta's co-authors include Agnese Latorre, Vito Lorusso, Annarita Fanizzi, Raffaella Massafra, Daniele La Forgia, Evaristo Maiello, Giuseppe Colucci, Pasquale Tamborra, Alfredo Zito and Vittorio Didonna and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Francesco Giotta

90 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Francesco Giotta Italy	21	574	258	255	230	155	98	1.1k
Olorunsola F. Agbaje United Kingdom	15	438 0.8×	171 0.7×	176 0.7×	262 1.1×	201 1.3×	26	971
S. Sabater Spain	18	253 0.4×	339 1.3×	622 2.4×	133 0.6×	73 0.5×	74	1.3k
Katarzyna J. Jerzak Canada	18	621 1.1×	538 2.1×	129 0.5×	209 0.9×	60 0.4×	100	1.2k
Chan‐Young Ock South Korea	17	508 0.9×	276 1.1×	233 0.9×	150 0.7×	130 0.8×	98	989
Isabel Amendoeira Portugal	15	617 1.1×	369 1.4×	224 0.9×	449 2.0×	179 1.2×	45	1.5k
Rita De Sanctis Italy	19	488 0.9×	622 2.4×	160 0.6×	153 0.7×	33 0.2×	106	1.2k
Jin Yang China	20	406 0.7×	334 1.3×	58 0.2×	255 1.1×	68 0.4×	68	1.3k
Xianghua Ye China	20	310 0.5×	205 0.8×	258 1.0×	100 0.4×	35 0.2×	58	1.1k
Henrik Hellborg Sweden	18	667 1.2×	293 1.1×	107 0.4×	355 1.5×	24 0.2×	24	1.2k
Belinda Lee Australia	19	549 1.0×	189 0.7×	174 0.7×	255 1.1×	23 0.1×	103	1.2k

Countries citing papers authored by Francesco Giotta

Since Specialization

Citations

This map shows the geographic impact of Francesco Giotta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesco Giotta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesco Giotta more than expected).

Fields of papers citing papers by Francesco Giotta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesco Giotta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesco Giotta. The network helps show where Francesco Giotta may publish in the future.

Co-authorship network of co-authors of Francesco Giotta

This figure shows the co-authorship network connecting the top 25 collaborators of Francesco Giotta. A scholar is included among the top collaborators of Francesco Giotta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesco Giotta. Francesco Giotta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fedele, Palma, Matteo Landriscina, Antonio Cusmai, et al.. (2024). Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study. Cancers. 16(20). 3442–3442. 2 indexed citations

Conte, Luana, Roberto Lupo, Stefano Botti, et al.. (2024). Knowledge and Misinformation About Breast Cancer Risk Factors, Symptoms, and Prevention Among Healthy and Affected Women: A Study on 2375 Italian Participants. Healthcare. 12(21). 2126–2126.

Fedele, Palma, Matteo Landriscina, Antonio Cusmai, et al.. (2024). Standard Versus Reduced CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter Study. Journal of Clinical Medicine. 13(23). 7441–7441. 1 indexed citations

Comes, Maria Colomba, Annarita Fanizzi, Samantha Bove, et al.. (2024). Explainable 3D CNN based on baseline breast DCE-MRI to give an early prediction of pathological complete response to neoadjuvant chemotherapy. Computers in Biology and Medicine. 172. 108132–108132. 8 indexed citations

Rizzo, Alessandro, L. Rinaldi, Raffaella Massafra, et al.. (2023). 412P Sacituzumab govitecan versus chemotherapy for metastatic breast cancer: A meta-analysis on safety outcomes. Annals of Oncology. 34. S356–S356. 1 indexed citations

Fanizzi, Annarita, Domenico Pomarico, Alessandro Rizzo, et al.. (2023). Machine learning survival models trained on clinical data to identify high risk patients with hormone responsive HER2 negative breast cancer. Scientific Reports. 13(1). 8575–8575. 5 indexed citations

Monaco, Antonio Di, et al.. (2022). Uno strano caso di tachicardia a QRS largo in corso di chemioterapia con paclitaxel. Giornale italiano di cardiologia. 23(4). 295–298.

Conté, Pierfranco, Antonio Frassoldati, Giancarlo Bisagni, et al.. (2021). 41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial. Annals of Oncology. 32. S37–S37. 4 indexed citations

Giotta, Francesco, et al.. (2020). PSYCHOLOGICAL RESILIENCE IN CANCER PATIENTS AND SURVIVORS DURING THE COVID-19 PANDEMIC. SHILAP Revista de lepidopterología. 3 indexed citations

10.

Guarneri, Valentina, Maria Vittoria Dieci, Giancarlo Bisagni, et al.. (2020). 19P PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study. Annals of Oncology. 31. S23–S23. 3 indexed citations

11.

Conté, Pierfranco, Valentina Guarneri, Giancarlo Bisagni, et al.. (2018). 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio. Annals of Oncology. 29. viii705–viii705. 5 indexed citations

12.

Steger, Guenther G., Francesco Giotta, N. Tubiana-Mathieu, et al.. (2017). Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study. Clinical Breast Cancer. 18(1). e41–e47. 7 indexed citations

13.

Russo, Francesco, Michele Linsalata, Caterina Clemente, et al.. (2013). The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study. BMC Cancer. 13(1). 56–56. 43 indexed citations

14.

Clavarezza, Matteo, Giorgio Mustacchi, Andrea Casadei‐Gardini, et al.. (2012). Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study. BMC Cancer. 12(1). 216–216. 6 indexed citations

15.

Vici, Patrizia, Giuseppe Colucci, Francesco Giotta, et al.. (2011). A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. Journal of Experimental & Clinical Cancer Research. 30(1). 39–39. 18 indexed citations

16.

Vici, Patrizia, Francesco Giotta, Luigi Di Lauro, et al.. (2011). A Multicenter Phase II Randomized Trial of Docetaxel/Gemcitabine versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Gruppo Oncologico Italia Meridionale Study. Oncology. 81(3-4). 230–236. 7 indexed citations

17.

Vici, Patrizia, Luigi Di Lauro, Domenico Sergi, et al.. (2008). A Phase II Trial of Docetaxel and Vinorelbine in Patients with Advanced Breast Cancer Previously Treated with Anthracyclines. Oncology. 75(3-4). 175–181. 11 indexed citations

18.

Valerio, Maria Rosaria, Manuela G. López, Mario Brandi, et al.. (2004). GRUPPO ONCOLOGICO ITALIA MERIDIONALE. NOVEL ASSOCIATION WITH GEMCITABINE AND DOCETAXEL AS SALVAGE CHEMOTHERAPY IN METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ANTHRACYCLINES: RESULT OF A NULTICENTER PHASE II STUDY. Seminars in Oncology. 2004. 9–13. 1 indexed citations

19.

Oliva, Stefano, et al.. (2003). Prinzmetal's Variant Angina During Cis-Diamminodichloroplatinum (CDDP) Administration: Case Report. Journal of Chemotherapy. 15(1). 89–90. 3 indexed citations

20.

Galetta, Domenico, Vittorio Gebbia, Francesco Giotta, et al.. (2002). Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale. Lung Cancer. 38(1). 79–84. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact